What's Happening?
Circle Pharma has announced a publication in Nature detailing robust pre-clinical anti-tumor activity of its cyclin A/B RxL inhibitor, CID-078. The research highlights the inhibitor's ability to selectively kill E2F-high tumor cells by disrupting protein interactions critical to cell cycle regulation. CID-078 is currently in Phase 1 clinical trials for patients with advanced solid tumors, showcasing the potential of Circle Pharma's MXMO platform to develop oral, cell-permeable macrocycle therapies.
Why It's Important?
This publication underscores the potential of Circle Pharma's innovative approach to cancer treatment, targeting historically undruggable proteins like cyclins. The findings could lead to new therapeutic options for cancers driven by high E2F activity, such as small cell lung cancer and triple-negative breast cancer. The success of CID-078 in clinical trials could significantly impact cancer treatment paradigms and enhance Circle Pharma's position in the biopharmaceutical industry.
What's Next?
Circle Pharma is advancing CID-078 through Phase 1 clinical trials, aiming to translate pre-clinical findings into effective cancer therapies. The company continues to leverage its MXMO platform to develop additional macrocycle therapeutics targeting cyclins and other challenging proteins.
